| 1.45 -0.25 (-14.71%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.18 | 1-year : | 2.55 |
| Resists | First : | 1.87 | Second : | 2.18 |
| Pivot price | 1.38  |
|||
| Supports | First : | 1.33 | Second : | 1 |
| MAs | MA(5) : | 1.66 |
MA(20) : | 1.32 |
| MA(100) : | 1.35 |
MA(250) : | 2.89 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 75.3 |
D(3) : | 85.7 |
| RSI | RSI(14): 54.3 |
|||
| 52-week | High : | 4.98 | Low : | 0.77 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ADCT ] has closed below upper band by 42.5%. Bollinger Bands are 7.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.73 - 1.74 | 1.74 - 1.74 |
| Low: | 1.38 - 1.39 | 1.39 - 1.4 |
| Close: | 1.43 - 1.45 | 1.45 - 1.46 |
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Fri, 09 Oct 2026
ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull Thesis - Seeking Alpha
Thu, 08 Oct 2026
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements - PR Newswire
Thu, 13 Aug 2026
ADC Therapeutics SA (ADCT) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles ... - Yahoo Finance
Thu, 13 Aug 2026
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates - PR Newswire
Thu, 13 Aug 2026
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Wed, 12 Aug 2026
Earnings To Watch: ADC Therapeutics SA (ADCT) Q2 2026 -- GF Value Sees 125% Upside - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 128 (M) |
| Shares Float | 89 (M) |
| Held by Insiders | 14.4 (%) |
| Held by Institutions | 67.5 (%) |
| Shares Short | 6,900 (K) |
| Shares Short P.Month | 6,290 (K) |
| EPS | -0.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.79 |
| Profit Margin | -121.8 % |
| Operating Margin | -118.2 % |
| Return on Assets (ttm) | -19.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | -0.08 |
| Sales Per Share | 0.62 |
| EBITDA (p.s.) | -0.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -102 (M) |
| Levered Free Cash Flow | -68 (M) |
| PE Ratio | -2.42 |
| PEG Ratio | 0 |
| Price to Book value | -0.82 |
| Price to Sales | 2.32 |
| Price to Cash Flow | -1.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|